Cargando…
Reduced splenic uptake on (68)Ga-Pentixafor-PET/CT imaging in multiple myeloma - a potential imaging biomarker for disease prognosis
Beyond being a key factor for tumor growth and metastasis in human cancer, C-X-C motif chemokine receptor 4 (CXCR4) is also highly expressed by a number of immune cells, allowing for non-invasive read-out of inflammatory activity. With two recent studies reporting on prognostic implications of the s...
Autores principales: | , , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Ivyspring International Publisher
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9373803/ https://www.ncbi.nlm.nih.gov/pubmed/35966583 http://dx.doi.org/10.7150/thno.75847 |
_version_ | 1784767664276635648 |
---|---|
author | Kraus, Sabrina Klassen, Philipp Kircher, Malte Dierks, Alexander Habringer, Stefan Gäble, Alexander Kortüm, Klaus Martin Weinhold, Niels Ademaj-Kospiri, Valëza Werner, Rudolf A Schirbel, Andreas Buck, Andreas K Herhaus, Peter Wester, Hans-Jürgen Rosenwald, Andreas Weber, Wolfgang A Einsele, Hermann Keller, Ulrich Rasche, Leo Lapa, Constantin |
author_facet | Kraus, Sabrina Klassen, Philipp Kircher, Malte Dierks, Alexander Habringer, Stefan Gäble, Alexander Kortüm, Klaus Martin Weinhold, Niels Ademaj-Kospiri, Valëza Werner, Rudolf A Schirbel, Andreas Buck, Andreas K Herhaus, Peter Wester, Hans-Jürgen Rosenwald, Andreas Weber, Wolfgang A Einsele, Hermann Keller, Ulrich Rasche, Leo Lapa, Constantin |
author_sort | Kraus, Sabrina |
collection | PubMed |
description | Beyond being a key factor for tumor growth and metastasis in human cancer, C-X-C motif chemokine receptor 4 (CXCR4) is also highly expressed by a number of immune cells, allowing for non-invasive read-out of inflammatory activity. With two recent studies reporting on prognostic implications of the spleen signal in diffusion-weighted magnetic resonance imaging in patients with plasma cell dyscrasias, the aim of this study was to correlate splenic (68)Ga-Pentixafor uptake in multiple myeloma (MM) with clinical parameters and to evaluate its prognostic impact. Methods: Eighty-seven MM patients underwent molecular imaging with (68)Ga-Pentixafor-PET/CT. Splenic CXCR4 expression was semi-quantitatively assessed by peak standardized uptake values (SUV(peak)) and corresponding spleen-to-bloodpool ratios (TBR) and correlated with clinical and prognostic features as well as survival parameters. Results: (68)Ga-Pentixafor-PET/CT was visually positive in all MM patients with markedly heterogeneous tracer uptake in the spleen. CXCR4 expression determined by (68)Ga-Pentixafor-PET/CT corresponded with advanced disease and was inversely associated with the number of previous treatment lines as compared to controls or untreated smouldering multiple myeloma patients (SUV(peak)Spleen 4.06 ± 1.43 vs. 6.02 ± 1.16 vs. 7.33 ± 1.40; P < 0.001). Moreover, reduced splenic (68)Ga-Pentixafor uptake was linked to unfavorable clinical outcome. Patients with a low SUV(peak)Spleen (<3.35) experienced a significantly shorter overall survival of 5 months as compared to 62 months in patients with a high SUV(peak)Spleen >5.79 (P < 0.001). Multivariate Cox analysis confirmed SUV(peak)Spleen as an independent predictor of survival (HR 0.75; P = 0.009). Conclusion: These data suggest that splenic (68)Ga-Pentixafor uptake might provide prognostic information in pre-treated MM patients similar to what was reported for diffusion-weighted magnetic resonance imaging. Further research to elucidate the underlying biologic implications is warranted. |
format | Online Article Text |
id | pubmed-9373803 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Ivyspring International Publisher |
record_format | MEDLINE/PubMed |
spelling | pubmed-93738032022-08-12 Reduced splenic uptake on (68)Ga-Pentixafor-PET/CT imaging in multiple myeloma - a potential imaging biomarker for disease prognosis Kraus, Sabrina Klassen, Philipp Kircher, Malte Dierks, Alexander Habringer, Stefan Gäble, Alexander Kortüm, Klaus Martin Weinhold, Niels Ademaj-Kospiri, Valëza Werner, Rudolf A Schirbel, Andreas Buck, Andreas K Herhaus, Peter Wester, Hans-Jürgen Rosenwald, Andreas Weber, Wolfgang A Einsele, Hermann Keller, Ulrich Rasche, Leo Lapa, Constantin Theranostics Research Paper Beyond being a key factor for tumor growth and metastasis in human cancer, C-X-C motif chemokine receptor 4 (CXCR4) is also highly expressed by a number of immune cells, allowing for non-invasive read-out of inflammatory activity. With two recent studies reporting on prognostic implications of the spleen signal in diffusion-weighted magnetic resonance imaging in patients with plasma cell dyscrasias, the aim of this study was to correlate splenic (68)Ga-Pentixafor uptake in multiple myeloma (MM) with clinical parameters and to evaluate its prognostic impact. Methods: Eighty-seven MM patients underwent molecular imaging with (68)Ga-Pentixafor-PET/CT. Splenic CXCR4 expression was semi-quantitatively assessed by peak standardized uptake values (SUV(peak)) and corresponding spleen-to-bloodpool ratios (TBR) and correlated with clinical and prognostic features as well as survival parameters. Results: (68)Ga-Pentixafor-PET/CT was visually positive in all MM patients with markedly heterogeneous tracer uptake in the spleen. CXCR4 expression determined by (68)Ga-Pentixafor-PET/CT corresponded with advanced disease and was inversely associated with the number of previous treatment lines as compared to controls or untreated smouldering multiple myeloma patients (SUV(peak)Spleen 4.06 ± 1.43 vs. 6.02 ± 1.16 vs. 7.33 ± 1.40; P < 0.001). Moreover, reduced splenic (68)Ga-Pentixafor uptake was linked to unfavorable clinical outcome. Patients with a low SUV(peak)Spleen (<3.35) experienced a significantly shorter overall survival of 5 months as compared to 62 months in patients with a high SUV(peak)Spleen >5.79 (P < 0.001). Multivariate Cox analysis confirmed SUV(peak)Spleen as an independent predictor of survival (HR 0.75; P = 0.009). Conclusion: These data suggest that splenic (68)Ga-Pentixafor uptake might provide prognostic information in pre-treated MM patients similar to what was reported for diffusion-weighted magnetic resonance imaging. Further research to elucidate the underlying biologic implications is warranted. Ivyspring International Publisher 2022-08-08 /pmc/articles/PMC9373803/ /pubmed/35966583 http://dx.doi.org/10.7150/thno.75847 Text en © The author(s) https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/). See http://ivyspring.com/terms for full terms and conditions. |
spellingShingle | Research Paper Kraus, Sabrina Klassen, Philipp Kircher, Malte Dierks, Alexander Habringer, Stefan Gäble, Alexander Kortüm, Klaus Martin Weinhold, Niels Ademaj-Kospiri, Valëza Werner, Rudolf A Schirbel, Andreas Buck, Andreas K Herhaus, Peter Wester, Hans-Jürgen Rosenwald, Andreas Weber, Wolfgang A Einsele, Hermann Keller, Ulrich Rasche, Leo Lapa, Constantin Reduced splenic uptake on (68)Ga-Pentixafor-PET/CT imaging in multiple myeloma - a potential imaging biomarker for disease prognosis |
title | Reduced splenic uptake on (68)Ga-Pentixafor-PET/CT imaging in multiple myeloma - a potential imaging biomarker for disease prognosis |
title_full | Reduced splenic uptake on (68)Ga-Pentixafor-PET/CT imaging in multiple myeloma - a potential imaging biomarker for disease prognosis |
title_fullStr | Reduced splenic uptake on (68)Ga-Pentixafor-PET/CT imaging in multiple myeloma - a potential imaging biomarker for disease prognosis |
title_full_unstemmed | Reduced splenic uptake on (68)Ga-Pentixafor-PET/CT imaging in multiple myeloma - a potential imaging biomarker for disease prognosis |
title_short | Reduced splenic uptake on (68)Ga-Pentixafor-PET/CT imaging in multiple myeloma - a potential imaging biomarker for disease prognosis |
title_sort | reduced splenic uptake on (68)ga-pentixafor-pet/ct imaging in multiple myeloma - a potential imaging biomarker for disease prognosis |
topic | Research Paper |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9373803/ https://www.ncbi.nlm.nih.gov/pubmed/35966583 http://dx.doi.org/10.7150/thno.75847 |
work_keys_str_mv | AT kraussabrina reducedsplenicuptakeon68gapentixaforpetctimaginginmultiplemyelomaapotentialimagingbiomarkerfordiseaseprognosis AT klassenphilipp reducedsplenicuptakeon68gapentixaforpetctimaginginmultiplemyelomaapotentialimagingbiomarkerfordiseaseprognosis AT kirchermalte reducedsplenicuptakeon68gapentixaforpetctimaginginmultiplemyelomaapotentialimagingbiomarkerfordiseaseprognosis AT dierksalexander reducedsplenicuptakeon68gapentixaforpetctimaginginmultiplemyelomaapotentialimagingbiomarkerfordiseaseprognosis AT habringerstefan reducedsplenicuptakeon68gapentixaforpetctimaginginmultiplemyelomaapotentialimagingbiomarkerfordiseaseprognosis AT gablealexander reducedsplenicuptakeon68gapentixaforpetctimaginginmultiplemyelomaapotentialimagingbiomarkerfordiseaseprognosis AT kortumklausmartin reducedsplenicuptakeon68gapentixaforpetctimaginginmultiplemyelomaapotentialimagingbiomarkerfordiseaseprognosis AT weinholdniels reducedsplenicuptakeon68gapentixaforpetctimaginginmultiplemyelomaapotentialimagingbiomarkerfordiseaseprognosis AT ademajkospirivaleza reducedsplenicuptakeon68gapentixaforpetctimaginginmultiplemyelomaapotentialimagingbiomarkerfordiseaseprognosis AT wernerrudolfa reducedsplenicuptakeon68gapentixaforpetctimaginginmultiplemyelomaapotentialimagingbiomarkerfordiseaseprognosis AT schirbelandreas reducedsplenicuptakeon68gapentixaforpetctimaginginmultiplemyelomaapotentialimagingbiomarkerfordiseaseprognosis AT buckandreask reducedsplenicuptakeon68gapentixaforpetctimaginginmultiplemyelomaapotentialimagingbiomarkerfordiseaseprognosis AT herhauspeter reducedsplenicuptakeon68gapentixaforpetctimaginginmultiplemyelomaapotentialimagingbiomarkerfordiseaseprognosis AT westerhansjurgen reducedsplenicuptakeon68gapentixaforpetctimaginginmultiplemyelomaapotentialimagingbiomarkerfordiseaseprognosis AT rosenwaldandreas reducedsplenicuptakeon68gapentixaforpetctimaginginmultiplemyelomaapotentialimagingbiomarkerfordiseaseprognosis AT weberwolfganga reducedsplenicuptakeon68gapentixaforpetctimaginginmultiplemyelomaapotentialimagingbiomarkerfordiseaseprognosis AT einselehermann reducedsplenicuptakeon68gapentixaforpetctimaginginmultiplemyelomaapotentialimagingbiomarkerfordiseaseprognosis AT kellerulrich reducedsplenicuptakeon68gapentixaforpetctimaginginmultiplemyelomaapotentialimagingbiomarkerfordiseaseprognosis AT rascheleo reducedsplenicuptakeon68gapentixaforpetctimaginginmultiplemyelomaapotentialimagingbiomarkerfordiseaseprognosis AT lapaconstantin reducedsplenicuptakeon68gapentixaforpetctimaginginmultiplemyelomaapotentialimagingbiomarkerfordiseaseprognosis |